» Articles » PMID: 26315510

Associations Between Circulating Endostatin Levels and Vascular Organ Damage in Systemic Sclerosis and Mixed Connective Tissue Disease: an Observational Study

Abstract

Introduction: Systemic sclerosis (SSc) and mixed connective tissue disease (MCTD) are chronic immune-mediated disorders complicated by vascular organ damage. The aim of this study was to examine the serum levels of the markers of neoangiogenesis: endostatin and vascular endothelial growth factor (VEGF), in our unselected cohorts of SSc and MCTD.

Methods: Sera of SSc patients (N = 298) and MCTD patients (N = 162) from two longitudinal Norwegian cohorts were included. Blood donors were included as controls (N = 100). Circulating VEGF and endostatin were analyzed by enzyme immunoassay.

Results: Mean endostatin levels were increased in SSc patients 93.7 (37) ng/ml (P < .001) and MCTD patients 83.2 (25) ng/ml (P < .001) compared to controls 65.1 (12) ng/ml. Median VEGF levels were elevated in SSc patients 209.0 (202) pg/ml compared to MCTD patients 181.3 (175) pg/ml (P = .017) and controls 150.0 (145) pg/ml (P < .001). Multivariable analysis of SSc subsets showed that pulmonary arterial hypertension (coefficient 15.7, 95 % CI: 2.2-29.2, P = .023) and scleroderma renal crisis (coefficient 77.6, 95 % CI: 59.3-100.0, P < .001) were associated with elevated endostatin levels. Multivariable analyses of MCTD subsets showed that digital ulcers were associated with elevated endostatin levels (coefficient 10.5, 95 % CI: 3.2-17.8, P = .005). The risk of death increased by 1.6 per SD endostatin increase (95 % CI: 1.2-2.1, P = .001) in the SSc cohort and by 1.6 per SD endostatin increase (95 % CI: 1.0-2.4, P = .041) in the MCTD cohort after adjustments to known risk factors.

Conclusions: Endostatin levels were elevated in patients with SSc and MCTD, particularly SSc patients with pulmonary arterial hypertension and scleroderma renal crisis, and MCTD patients with digital ulcers. Elevated endostatin levels were also associated with increased all-cause mortality during follow-up in both groups of patients. We propose that endostatin might indicate the degree of vascular injury in SSc and MCTD patients.

Citing Articles

Endostatin as a biomarker of systemic sclerosis: insights from a systematic review and meta-analysis.

Mangoni A, Zinellu A Front Immunol. 2025; 15:1450176.

PMID: 39763677 PMC: 11701163. DOI: 10.3389/fimmu.2024.1450176.


Recent developments in connective tissue disease associated pulmonary arterial hypertension.

Rodolfi S, Ong V, Denton C Int J Cardiol Congenit Heart Dis. 2024; 16:100513.

PMID: 39712533 PMC: 11657338. DOI: 10.1016/j.ijcchd.2024.100513.


Vascular endothelial growth factor as a potential biomarker in systemic sclerosis: a systematic review and meta-analysis.

Zinellu A, Mangoni A Front Immunol. 2024; 15:1442913.

PMID: 39669565 PMC: 11634811. DOI: 10.3389/fimmu.2024.1442913.


Soluble Proteoglycans and Proteoglycan Fragments as Biomarkers of Pathological Extracellular Matrix Remodeling.

Kemberi M, Minns A, Santamaria S Proteoglycan Res. 2024; 2(4):e70011.

PMID: 39600538 PMC: 11587194. DOI: 10.1002/pgr2.70011.


Collagen 18A1/Endostatin Expression in the Progression of Right Ventricular Remodeling and Dysfunction in Pulmonary Arterial Hypertension.

Ambade A, Naranjo M, Tuhy T, Yu R, Marimoutou M, Everett A Am J Respir Cell Mol Biol. 2024; 71(3):343-355.

PMID: 38861354 PMC: 11376241. DOI: 10.1165/rcmb.2024-0039OC.


References
1.
Dodd T, Wiggins L, Hutcheson R, Smith E, Musiyenko A, Hysell B . Impaired coronary collateral growth in the metabolic syndrome is in part mediated by matrix metalloproteinase 12-dependent production of endostatin and angiostatin. Arterioscler Thromb Vasc Biol. 2013; 33(6):1339-49. PMC: 3753795. DOI: 10.1161/ATVBAHA.113.301533. View

2.
Hoffmann-Vold A, Molberg O, Midtvedt O, Garen T, Gran J . Survival and causes of death in an unselected and complete cohort of Norwegian patients with systemic sclerosis. J Rheumatol. 2013; 40(7):1127-33. DOI: 10.3899/jrheum.121390. View

3.
Hoffmann-Vold A, Midtvedt O, Molberg O, Garen T, Gran J . Prevalence of systemic sclerosis in south-east Norway. Rheumatology (Oxford). 2012; 51(9):1600-5. DOI: 10.1093/rheumatology/kes076. View

4.
Gunnarsson R, Aalokken T, Molberg O, Lund M, Mynarek G, Lexberg A . Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis. 2012; 71(12):1966-72. DOI: 10.1136/annrheumdis-2011-201253. View

5.
Galie N, Hoeper M, Humbert M, Torbicki A, Vachiery J, Barbera J . Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the.... Eur Heart J. 2009; 30(20):2493-537. DOI: 10.1093/eurheartj/ehp297. View